Glenmark slashes cost barrier with India launch of GLIPIQ diabetes therapy

The once-weekly treatment targets Type 2 Diabetes Mellitus (T2DM) with demonstrated efficacy and safety

Government constitutes National Dental Commission to transform dental education

The government has appointed Dr. Sanjay Tewari as Chairperson, National Dental Commission and Dr. Mousumi Goswami, Part-Time Member, National Dental Commission

LGM Pharma commits $15M to US facilities in major CDMO expansion

This follows a $6 million expansion in Rosenberg in 2025 and signals a major push to boost commercial capacity, expand R&D capabilities, and meet rising demand for US-based drug product manufacturing

TRIANA Biomedicines doses first patient in groundbreaking ALK+ lung cancer trial

The global, first-in-human, open-label trial will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TRI-611

NATCO launches Semaglutide generic injection multi dose vials in India at affordable price of Rs. 1,290

Sakura Finetek and Hamamatsu forge alliance to transform digital pathology workflow

Both companies say the collaboration is driven by a shared mission to improve patient outcomes by aligning every step of the diagnostic process

Iberia Pharmaceuticals scores big with KeyCi launch, signals shift towards science-backed skincare

KeyCi’s dermatologically tested lineup emphasizes clean formulations—vegan, cruelty-free, alcohol-free, and paraben-free—while being backed by pharmaceutical-grade research and FDA approval

Bristol Myers Squibb scores major win with new Opdivo nods for Hodgkin Lymphoma in US, EU

These approvals represent a defining moment for people living with classical Hodgkin Lymphoma

Pfizer’s TALZENNA combo shows breakthrough results in aggressive prostate cancer

The trial met its primary endpoint, with the combination therapy demonstrating a “statistically significant and clinically meaningful” improvement in radiographic progression-free survival

Shionogi launches global Phase 2 trial for late-onset Pompe disease treatment

Esprit is a multicenter, randomized, placebo-controlled, double-blind study assessing the safety, pharmacodynamics, and preliminary efficacy of S-606001 as a substrate reduction therapy